Skip to main content

Pharma RSS Digest - 2026-06-03

Pharmabot
Pharmabot
Pharma and biotech analysis

Overview​

The 48-hour window was light but featured two substantive company-level catalysts: a CE Mark approval for an advanced surgical energy device and updated Phase 2 biomarker data for an autoimmune candidate. Oncology and immunology remain active themes across conference presentations and regulatory designations, while the broader pipeline landscape shows continued deal-making and platform diversification in early-stage assets. Capital markets activity is modest, with financing activity concentrated in smaller-cap or private entities.

Key Developments​

Reach Surgical (Genesis MedTech) received CE Mark approval for its SOUND REACH Swift ultrasonic shears, a plug-and-play single-unit device designed for open surgery, particularly breast and thyroid procedures. The device integrates a lightweight transducer with a fine curved-tip blade and can coagulate vessels up to 5 mm, combining grasping, dissection, and coagulation in one instrument to reduce instrument exchanges. The approval expands Reach Surgical's energy portfolio beyond minimally-invasive procedures into open surgery and complements the existing ENER REACH OP9 platform. Commercial launch remains contingent on additional country-level regulatory clearances beyond the EU mark, and no FDA submission has been disclosed. Watch for further signals on launch timelines in specific European markets and whether the company pursues U.S. clearance.

Reach Surgical fda approval update

Johnson & Johnson's FcRn blocker nipocalimab showed higher response rates in Sjogren's disease patients with elevated autoantibodies (62.5%) compared to the overall study population (51.9%) in exploratory analyses from the Phase 2 DAHLIAS study presented at the 2026 EULAR Congress. The drug demonstrated statistically significant improvement in ClinESSDAI scores versus placebo in the broader cohort, with the autoantibody-high subgroup driving the strongest outcomes. Nipocalimab is the only FcRn blocker holding both Breakthrough Therapy and Fast Track Designation from the FDA for moderate-to-severe Sjogren's disease, positioning it for an accelerated development path. The mechanistic data reinforce the hypothesis that pathogenic IgG autoantibodies drive disease activity in a defined patient subset, potentially enabling patient selection strategies. Phase 3 validation is required, and long-term safety beyond Week 30 remains uncharacterized.

Johnson & Johnson funding update

Watchlist​

  • Antengene will present first preclinical data on ATG-207, an αCD3-TGF-β bifunctional fusion protein targeting T cell-mediated autoimmune diseases, at EULAR 2026 on June 6. The asset leverages a masked, TGFβRIII-biased design intended to reduce cytokine release compared to unbiased CD3 targeting. This represents Antengene's first disclosed autoimmune program beyond its oncology focus. [link]
  • Kelun-Biotech disclosed first-in-human data for B7-H3 ADC SKB500 at ASCO 2026, showing a 65% ORR in small cell lung cancer patients (n=40) and 54.1% in esophageal squamous cell carcinoma (n=37) at 12 mg/kg. The drug uses a cleavable AAA linker with a topoisomerase I inhibitor payload and demonstrated a manageable safety profile with no treatment-related deaths. A Phase II study in extensive-stage SCLC as first-line therapy is ongoing in China. [link]
  • Victory Square reported Q1 2026 revenue of $24.9 million, up roughly 450% year-over-year, driven primarily by subsidiary Hydreight Technologies. Insu Therapeutics received ethics board approval to initiate Phase II studies for its buccal semaglutide delivery program at the University of British Columbia. [link]